3.49
-0.01(-0.29%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
December 15, 2021
| Name | Title | Pay | Year Born |
| Mr. Pierluigi Paracchi | Co-Founder, Chairman, Chief Executive Officer & GM | 0 | 1973 |
| Dr. Carlo Russo M.D. | Chief Medical Officer & Head of Development | 0 | 1953 |
| Dr. Stefania Mazzoleni Ph.D. | Director of Program Development | 0 | 1982 |
| Ms. Barbara Regonini | Director of Finance | 0 | 1973 |
| Mr. Richard B. Slansky | Chief Financial Officer | 0 | 1958 |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder & Chairman of the Executive Scientific Board | 0 | 1959 |
| Dr. Bernard Rudolph Gentner M.D., Ph.D. | Co-Founder & Member of the Executive Scientific Board | 0 | 1975 |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.